These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 16312318)

  • 1. In vitro evaluation of new beta-lactamase inhibitor: YTR830H and derivatives.
    Ishida N; Higashitani F; Hanehara C; Uji T; Inoue M; Mitsuhashi S
    J Chemother; 1989 Jul; 1(4 Suppl):88-9. PubMed ID: 16312318
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
    Nord CE
    J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
    [No Abstract]   [Full Text] [Related]  

  • 3. Orally administered recombinant metallo-beta-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice.
    Stiefel U; Harmoinen J; Koski P; Kääriäinen S; Wickstrand N; Lindevall K; Pultz NJ; Bonomo RA; Helfand MS; Donskey CJ
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5190-1. PubMed ID: 16304203
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro efficacy of ceftriaxone/sulbactam against Escherichia coli isolates producing CTX-M-15 extended-spectrum beta-lactamase.
    Shahid M; Singhai M; Malik A; Shukla I; Khan HM; Shujatullah F; Tahira F
    J Antimicrob Chemother; 2007 Jul; 60(1):187-8. PubMed ID: 17491002
    [No Abstract]   [Full Text] [Related]  

  • 5. In-vitro evaluation of "piperacillin and tazobactum" combination in a tertiary-care hospital--a preliminary study.
    Kumari N; Mohapatra TM; Rai A; Bhattacharya SK
    Indian J Pathol Microbiol; 2006 Jan; 49(1):57-8. PubMed ID: 16625981
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro activity of YTR-830H in combination with beta-lactamase unstable beta-lactams.
    Chin NX; Neu HC
    J Chemother; 1989 Jul; 1(4 Suppl):90-2. PubMed ID: 16312319
    [No Abstract]   [Full Text] [Related]  

  • 7. Synergistic activity of piperacillin: YTR-830H combinations in vitro and in vivo.
    Kuck NA; Petersen PJ; Weiss WJ; Jacobus NV; Testa RT; Tally FP
    J Chemother; 1989 Jul; 1(4 Suppl):105-6. PubMed ID: 16312325
    [No Abstract]   [Full Text] [Related]  

  • 8. Detection of bacterial strains producing sulbactam- or tazobactam-sensitive beta-lactamases by the use of disks containing the inhibitors alone instead of combining them with antibiotics.
    Banic S
    APMIS; 2006 Jan; 114(1):3-9. PubMed ID: 16499654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irreproducible piperacillin/tazobactam minimum inhibitory concentrations in microdilution tests with Escherichia coli strains.
    Thomson KS; Black J; Moland ES; Reuben J; Wiles T; Brasso W
    Int J Antimicrob Agents; 2008 Jan; 31(1):83-5. PubMed ID: 17996426
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of YTR830H and piperacillin after intravenous coadministration.
    Cheung WK; Greene DS; Kuye O; Shin K; Tonelli AP; Houston A; Hibberd M; Faulkner RD; Silber BM
    J Chemother; 1989 Jul; 1(4 Suppl):507-8. PubMed ID: 16312506
    [No Abstract]   [Full Text] [Related]  

  • 11. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
    Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
    Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YTR-830H: its origin, the present and the future.
    Yamabe S
    J Chemother; 1989 Jul; 1(4 Suppl):87. PubMed ID: 16312317
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluating the ototoxicity of topical piperacillin-tazobactam.
    Jang CH; Park H; Cho YB; Choi CH
    Int J Pediatr Otorhinolaryngol; 2008 Dec; 72(12):1815-21. PubMed ID: 18845345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of sensitivity of different organisms to cefepime and tazobactum (megapime XP) in comparison to cefepime and ceftazidime.
    Pal RB; Pal P; Venkatesh V; Kulkarni KP
    J Indian Med Assoc; 2008 Sep; 106(9):605-6, 611. PubMed ID: 19552092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
    Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
    Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and beta-lactamase inhibitory properties of 2 beta-(thio-substituted methyl)-penam 1,1-dioxides.
    Tanaka H; Tanaka M; Nakai A; Yamada S; Ishida N; Otani T; Torii S
    J Antibiot (Tokyo); 1988 Apr; 41(4):579-82. PubMed ID: 2836350
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthesis and biological evaluation of penem inhibitors of bacterial signal peptidase.
    Harris DA; Powers ME; Romesberg FE
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3787-90. PubMed ID: 19427205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperacillin + tazobactam: fixed ratio versus fixed concentration synergism studies.
    Cullmann W; Stieglitz M
    J Chemother; 1989 Jul; 1(4 Suppl):85-6. PubMed ID: 16312316
    [No Abstract]   [Full Text] [Related]  

  • 19. Understanding the longevity of the beta-lactam antibiotics and of antibiotic/beta-lactamase inhibitor combinations.
    Buynak JD
    Biochem Pharmacol; 2006 Mar; 71(7):930-40. PubMed ID: 16359643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thermophilic multidrug-resistant Campylobacter fetus infection with hypersplenism and histiocytic phagocytosis in a patient with acquired immunodeficiency syndrome.
    Anstead G; Jorgensen J; Craig F; Blaser M; Patterson T
    Clin Infect Dis; 2001 Jan; 32(2):295-6. PubMed ID: 11170921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.